Stępniak Anna
3 Chair and Department of Gynaecology, Medical University of Lublin, Lublin, Poland.
Prz Menopauzalny. 2018 Dec;17(4):141-143. doi: 10.5114/pm.2018.81733. Epub 2018 Dec 31.
Uterine fibroids are considered to be the most common benign tumours in females. The vast majority of these tumours are incidental findings and do not require any treatment. Symptomatic fibroids, with ailments such as abnormal uterine bleeding, dysmenorrhoea, pelvic pain, impaired urination, bowel dysfunction, infertility, and recurrent pregnancy loss, are indicated for medical treatment. Surgery remains a first-line treatment of symptomatic uterine fibroids; however, minimally invasive techniques and pharmacological management have become more available and popular. Among minimally invasive techniques uterine artery embolization (UAE) is the most well-established uterine preserving treatment. UAE was first introduced in obstetrics and gynaecology in 1987 and since then many studies have shown the safety and efficacy of UAE in fibroid treatment with low rates of complications. In this review we present a novel approach to UAE, which reflects the current state of knowledge based on recent clinical trials and long-term post-procedural follow-up.
子宫肌瘤被认为是女性最常见的良性肿瘤。这些肿瘤绝大多数是偶然发现的,不需要任何治疗。有症状的肌瘤,如异常子宫出血、痛经、盆腔疼痛、排尿障碍、肠道功能障碍、不孕和复发性流产等疾病,适合进行医学治疗。手术仍然是有症状子宫肌瘤的一线治疗方法;然而,微创技术和药物治疗变得更加可行和流行。在微创技术中,子宫动脉栓塞术(UAE)是最成熟的保留子宫的治疗方法。UAE于1987年首次引入妇产科,从那时起,许多研究表明UAE在肌瘤治疗中的安全性和有效性,并发症发生率较低。在本综述中,我们提出了一种UAE的新方法,该方法反映了基于近期临床试验和术后长期随访的当前知识状态。